FGF10 and metabolic disease: More recently, it has been suggested that the miR-327/FGF10/FGFR2 signaling axis may be a therapeutic target for treatment of obesity and metabolic diseases (Fischer et al., 2017) and that the crosstalk between miR-145-5p and FGF10 expression regulates vascular smooth muscle cells proliferation and migration (Shi et al., 2018).